RxDoctor Payments Data

Anca Goller, MD

Endocrinology, Diabetes & Metabolism · Maynard, MANPI 1083765036

Payments from drug & device makers

$1,113in general payments, 2019–2025

Across 54 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$144
  • Lilly USA, LLC$133
  • Novo Nordisk$125
  • Abbott$96
  • AstraZeneca$86
  • Medtronic$82
  • plus $445 from 12 others

What the payments were for

  • Food & beverage$1,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,113 in reported general payments places this provider in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$71,214
Medicare patients
379
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$224,667
JardianceEmpagliflozin109$140,789
TrulicityDulaglutide76$134,250
ForteoTeriparatide14$58,062
MounjaroTirzepatide42$45,595
FarxigaDapagliflozin Propanediol27$35,856
TradjentaLinagliptin28$32,881
JanuviaSitagliptin Phosphate28$25,035
GenotropinSomatropin12$23,044
Victoza 3-PakLiraglutide15$16,172
Testosterone87$12,077
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$10,286
Humalog Kwikpen U-100Insulin Lispro24$9,418
Tresiba Flextouch U-100Insulin Degludec12$8,684
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog$133$243,020146 claims
Novo NordiskOzempic$125$224,667148 claims
Boehringer IngelheimJardiance, Tradjenta$19$173,669137 claims
AstraZenecaFarxiga$86$35,85627 claims
AbbVieSynthroid$25$8,54887 claims
IBSA Pharma Inc.Tirosint$29$5,14019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

Other endocrinology, diabetes & metabolism in Maynard

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →